Search results for "Vaccines"
First COVID-19 vaccine receives interim recommendation, hydroxychloroquine ineffective for prophylaxis, and more
The FDA issued an emergency use authorization for the first mRNA vaccine against SARS-CoV-2, and the CDC's Advisory Committee on Immunization Practices made an interim recommendation for its use in those ages 16 years and older. Other research looked at postexposure prophylaxis, household SARS-CoV-2 transmission, and persistent COVID-19 symptoms.
https://immattersacp.org/weekly/archives/2020/12/15/1.htm
15 Dec 2020
CDC issues reminder on appropriate use of recombinant zoster vaccine
Early monitoring suggests that clinicians are confusing the administration and storage requirements of the older live attenuated virus vaccine with the recently approved recombinant zoster vaccine, the agency said.
https://immattersacp.org/weekly/archives/2018/06/05/5.htm
5 Jun 2018
Pandemic enters new phase with end of PHE
COVID-19 isn't gone, but the end of the U.S. public health emergency does mark some significant changes.
https://immattersacp.org/archives/2023/06/pandemic-enters-new-phase-with-end-of-phe.htm
1 Jun 2023
New research adds to data on symptoms after COVID-19, vaccines' effects
Several COVID-19 studies looked at persistent symptoms, while new vaccine research found limited antibody responses in some patients and advised on tests for clotting complications. Other studies quantified the target population for tocilizumab treatment and gender differences in infections.
https://immattersacp.org/weekly/archives/2021/05/25/1.htm
25 May 2021
Treatment for high-risk COVID-19 patients, vaccine news, research on health messaging
An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
https://immattersacp.org/weekly/archives/2021/07/20/1.htm
20 Jul 2021
Staying safe on social media
Despite the risks of impersonation or harassment, physicians say participating in social media has considerable professional and personal benefits.
https://immattersacp.org/archives/2023/06/staying-safe-on-social-media.htm
1 Jun 2023
New vaccine authorization and data, NIH on antibody treatment and ‘long COVID’
The Johnson & Johnson COVID-19 vaccine got an emergency use authorization, and an Israeli study provided more data on the Pfizer vaccine. The NIH recommended an antibody combo for outpatients and named long-term symptoms as post-acute sequelae of SARS-CoV-2 (PASC).
https://immattersacp.org/weekly/archives/2021/03/02/1.htm
2 Mar 2021
Earn trust, counter misinformation
Physicians are on the front lines of addressing medical misinformation, increasingly figuring out what to address and how.
https://immattersacp.org/archives/2023/06/earn-trust-counter-misinformation.htm
1 Jun 2023
Research on COVID-19 vaccines' duration, reactions, prioritization
Antibodies persisted six months after vaccination, and a graded dosing protocol allowed patients with reactions to a first shot to get a second. Surveyed Americans wanted to prioritize front-line workers and those with chronic conditions for vaccination, and a columnist finds reasons for hope.
https://immattersacp.org/weekly/archives/2021/04/13/1.htm
13 Apr 2021
Clot concerns with adenovirus COVID-19 vaccines, antibody treatment recommendations and data
Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23. The NIH updated its recommendations on monoclonal antibody treatments for outpatients.
https://immattersacp.org/weekly/archives/2021/04/20/1.htm
20 Apr 2021